Abstracts tagged "Psoriatic arthritis"

Abstract Number: 581 • 2012 ACR/ARHP Annual Meeting
Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Fatima Abji¹, Remy Pollock², Fawnda Pellett³, Vinod Chandran⁴ and Dafna D. Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated…
Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Iain B. McInnes³, Lluis Puig⁴, Proton Rahman⁵, Shu Li⁶, Yuhua Wang⁶, Mittie K. Doyle⁷, Alan Mendelsohn⁸ and Arthur Kavanaugh⁹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Tufts Medical Center, Boston, MA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Janssen Research and Development, LLC, PA, ⁷Janssen Research and Development, LLC/U of Penn, Spring House/Phila, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹UCSD School of Medicine, La Jolla, CA
Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…
Abstract Number: 590 • 2012 ACR/ARHP Annual Meeting
The Association Between KIR3DL1 Alleles and Psoriatic Arthritis
Remy Pollock¹, Jeffrey Berinstein², Arane Thavaneswaran², Fawnda Pellett³, Dafna D. Gladman⁴ and Vinod Chandran⁵, ¹Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Killer-cell immunoglobulin-like receptors (KIRs) are activating and inhibitory receptors that regulate NK and NK-T cells, which have been found in psoriatic plaques and synovial…
Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Bente Glintborg¹, Mikkel Østergaard², Niels Steen Krogh³, Martin Dehn Andersen⁴, Ulrik Tarp⁴, Anne Gitte Loft⁴, Hanne M. Lindegaard⁵, Mette Holland-Fischer⁶, Henrik Nordin⁴, Dorte Vendelbo Jensen⁴ and Merete L. Hetland², ¹Copenhagen University Hospital Gentofte, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³ZiteLab ApS, Copenhagen, Denmark, ⁴DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…
Abstract Number: 552 • 2012 ACR/ARHP Annual Meeting
Simple Questions in the Dermatology Office May Reasonably Exclude, but Do Not Reliably Identify Psoriatic Arthritis Patients: Results From the Center of Excellence for Psoriasis and Psoriatic Arthritis
Neha Garg¹, Atul A. Deodhar², Benjamin Ehst³, Andrew Blauvelt⁴, Jennifer Ku⁵ and Brian Truong⁴, ¹Internal Medicine, Division of arthritis and rheumatic diseases, Oregon Health and Sciences University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³Dermatology, Oregon Health and Sciences University, Portland, OR, ⁴Oregon Health and Sciences University, Portland, OR, ⁵Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR
Background/Purpose: Psoriatic arthritis (PsA) affects between 10-30% of patients with psoriasis (PsO), but is often missed when assessed in a dermatology clinic. The Center of…
Abstract Number: 2560 • 2012 ACR/ARHP Annual Meeting
Response and Drug Survival of 1^st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?
Karen M. Fagerli¹, Elisabeth Lie², Désirée van der Heijde³, Marte S. Heiberg⁴, Erik Rødevand⁵, Åse S. Lexberg⁶, Synnøve Kalstad⁷, Knut Mikkelsen⁸ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet hospital, Oslo, Norway, ⁵Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁶Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁷Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁸Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway
Background/Purpose: It is well established that methotrexate (MTX) co-medication improves efficacy of TNF-inhibitors (TNFi) in rheumatoid arthritis, while in ankylosing spondylitis it is widely accepted…
Abstract Number: 569 • 2012 ACR/ARHP Annual Meeting
Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁷, Chenglong Han⁸, Alan Mendelsohn⁹ and Mittie K. Doyle⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Johnson & Johnson Pharmaceutical Services, LLC., Malvern, PA, ⁹Immunology, Janssen Research & Development, LLC, Spring House, PA
Ustekinumab Improves Arthritis-related and Skin-related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes from Randomized and Double Blinded Phase III PSUMMIT…
Abstract Number: 2561 • 2012 ACR/ARHP Annual Meeting
Switching Between TNF-Inhibitors in Psoriatic Arthritis: Data From the NOR-DMARD Study
Karen M. Fagerli¹, Elisabeth Lie², Désirée van der Heijde³, Marte S. Heiberg⁴, Åse S. Lexberg⁵, Knut Mikkelsen⁶, Erik Rødevand⁷, Synnøve Kalstad⁸ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Rheumatology, Diakonhjemmet hospital, Oslo, Norway, ⁵Department of Rheumatology, Vestre Viken, Drammen, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁷Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁸Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Although TNF-inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA), some patients do not respond to or do not tolerate their first TNFi. The…
Abstract Number: 531 • 2012 ACR/ARHP Annual Meeting
Developmen and Validation of a New Instrument to Asess Health Related Quality of Life in Psoriasis Arthritis: The Vitacora Questionnaire
Juan Carlos Torre-Alonso¹, J. Santos-Rey², JM Ruiz-Martin³, P. Valdazo-De Diego⁴, Mireia Moreno⁵ and Juan-Antonio Fernández⁶, ¹Unit Rheumatology, Hospital Monte Naranco, Oviedo, Spain, ²Rheumatology, Toledo, Spain, ³Rheumatology, Viladecans, Spain, ⁴Rheumatology, Zamora, Spain, ⁵Rheumatology, Corporació Sanitària Parc Taulí, Sabadell, Spain, ⁶MP, Oviedo, Spain
Background/Purpose: To develop and validate a specific questionnaire to measure health-related quality of life (HRQoL) in adults with psoriasis arthritis (PA) for use in clinical…
Abstract Number: 2562 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Arthur Kavanaugh¹, Iain B. McInnes², Alice B. Gottlieb³, Lluis Puig⁴, Proton Rahman⁵, Christopher T. Ritchlin⁶, Shu Li⁷, Yuhua Wang⁸, Alan Mendelsohn⁹ and Mittie K. Doyle⁷, ¹UCSD School of Medicine, La Jolla, CA, ²University of Glasgow, Glasgow, United Kingdom, ³Tufts Medical Center, Boston, MA, ⁴Universitat Autònoma de Barcelona, ⁵Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁶Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁷Janssen Research & Development, LLC, Spring House, PA, ⁸Janssen Research & Development, LLC., Spring House, PA, ⁹Immunology, Janssen Research & Development, LLC, Spring House, PA
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I StudyBackground/Purpose: To assess efficacy and safety of ustekinumab…
Abstract Number: 536 • 2012 ACR/ARHP Annual Meeting
Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort
Gail S. Kerr¹, Seema Qaiyumi², John S. Richards², Chesahna Kindred³, Sean A. Whelton⁴ and Florina M. Constantinescu⁵, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Rheumatology Section, Washington DC VA and Georgetown University, Washington, DC, ³Division of Dermatology, Howard University Hospital, Washington, DC, ⁴Division of Rheumatology, Georgetown University, Washington, DC, ⁵Rheumatology, Washington Hospital Center, Washington, DC
Background/Purpose: Few clinical studies describe psoriasis (PSO) and psoriatic arthritis (PsA) in ethnic minority groups. Previous patient-reported data show PSO/PsA to be less frequent in…
Abstract Number: 2491 • 2012 ACR/ARHP Annual Meeting
IL-17 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions
Jennifer Belasco¹, Hiroshi Mitsui¹, Mayte Suarez-Farinas¹, James S. Louie², Nathan Wei³, Nicholas Gulati¹ and James G. Krueger¹, ¹Krueger Laboratory, The Rockefeller University, New York, NY, ²Rheumatology, UCLA School of Medicine, Los Angeles, CA, ³Arthritis Treatment Center, Frederick, MD
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. It is known that treatment modalities are not equally effective for both skin…
Abstract Number: 537 • 2012 ACR/ARHP Annual Meeting
The Association of alpha7 Nicotinic Acetylcholine Receptor Polymorphisms with Psoriatic Arthritis and Its Interaction with Smoking
Lihi Eder¹, Vinod Chandran², Fawnda Pellett³, Remy Pollock⁴, Fatima Abji⁵, Adele Carty⁶, Sutharshini Shanmugarajah⁵, Cheryl Rosen⁷ and D. D. Gladman⁸, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Alpha7 nicotinic acetylcholine receptor (CHRNA7) is an ion channel that is gated by the binding of nicotinic ligands. Nicotine interacts with CHRNA7 leading to…
Abstract Number: 2223 • 2012 ACR/ARHP Annual Meeting
Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis
Remy Pollock¹, Fawnda Pellett², Vinod Chandran³ and Dafna D. Gladman⁴, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Chromatin modification enzymes regulate gene expression by altering the accessibility of promoters to transcription factors. Several of these enzymes are dysregulated in rheumatoid arthritis,…
Abstract Number: 108 • 2012 ACR/ARHP Annual Meeting
Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis
Christian Dejaco¹, Rusmir Husic², Judith Gretler³, Winfried B. Graninger⁴ and Josef Hermann², ¹Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Rheumatology, Medical University Graz, Graz, Austria, ³Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria
Background/Purpose: To compare ultrasound and clinical definitions of remission in psoriasis arthritis (PsA). Methods: Prospective study of 70 consecutive PsA patients [mean age 51.1 (±SD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.